\
&
Contact us
\
&
Contact us
About the programme
To support its ambition to make Europe an AI continent the EU, together with the EU Member States and stakeholders will develop an Apply AI Strategy. It will support the development of world class AI models in the EU and foster the integration of AI technologies into the EU’s most strategic sectors.
Artificial Intelligence is therefore a cross-cutting priority in the Digital Europe Programme.
Under the main work programme 2025-2027, Specific Objective 2 – AI Continent focuses on the following areas:
marie.timmermann@fwo.be
+32 2 550 15 59
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
AI Continent Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation Hubs
A new wave of calls under the Digital Europe programme is now open for submission. The Commission seeks project proposals for the following topics: AI Continent calls Health: Data ingestion capacities and data services for the European Genomic Data Infrastructure in the European Health Data Space: data tools Health: Data ingestion capacities a... read more
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
